2月24日 - ** 格兰马克制药公司GLEN.NS股价上涨 ~4% 至 1350.5 卢比
** 该公司与三名原告就 (link) 与非专利胆固醇药物 Zetia 相关的其余反垄断和消费者保护诉讼达成和解
** 原告包括 Humana HUM.N、Centene Corp 和 Kaiser Foundation Health Plan [RIC:RIC:KISERF.UL] ** 根据 700 万美元的和解条款，Glenmark 公司否认原告的指控，不承担任何责任。 ** 包括本交易日的涨幅在内，GLEN 的股价在过去 12 个月中上涨了 48.3 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.